To date, everolimus, an orally available mTOR inhibitor approved for the treatment of advanced breast cancer, neuroendocrine tumors of pancreatic origin, and advanced renal cell carcinoma, has met multiple clinical needs in oncology [1]. Here, MTOR is linked to breast carcinoma.